Find Erenumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

API REF. PRICE (USD/KG)

$
$ 0
API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077

FDA
03 Oct 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077

FDA
15 Aug 2022
Novartis, Amgen settle their yearslong Aimovig dispute
Novartis, Amgen settle their yearslong Aimovig dispute

02 Feb 2022

// E. Sagonowsky FIERCEPHARMA

https://www.fiercepharma.com/pharma/novartis-amgen-settle-their-dueling-lawsuits-over-migraine-drug-aimovig

E. Sagonowsky FIERCEPHARMA
02 Feb 2022
Aimovig displays superiority over topiramate in migraine study
Aimovig displays superiority over topiramate in migraine study

09 Nov 2021

// Anna Begley EUROPEANPHARMACEUTICALREVIEW

https://www.europeanpharmaceuticalreview.com/news/165242/aimovigdisplays-superiority-over-topiramate-in-migraine-study/

Anna Begley EUROPEANPHARMACEUTICALREVIEW
09 Nov 2021

https://www.fiercepharma.com/pharma/abbvie-pressures-biohaven-migraine-prevention-fda-approval-for-cgrp-blockbuster-to-be

Angus Liu FIERCEPHARMA
29 Sep 2021
AbbVie's oral migraine treatment atogepant nears FDA decision
AbbVie's oral migraine treatment atogepant nears FDA decision

20 Aug 2021

// Annalee Armstrong FIERCEBIOTECH

https://www.fiercebiotech.com/biotech/migraine-market-better-make-way-for-abbvie-as-oral-preventative-treatment-atogepant-poised

Annalee Armstrong FIERCEBIOTECH
20 Aug 2021

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 326,938,686

Year : 2023

Prescribers : 55770

Prescriptions : 333200

blank

02

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 302,037,671

Year : 2022

Prescribers : 55228

Prescriptions : 325457

blank

03

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 258,924,035

Year : 2021

Prescribers : 54670

Prescriptions : 330843

blank

04

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 206,119,545

Year : 2020

Prescribers : 47870

Prescriptions : 285011

blank

05

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 56,756

Year : 2020

Prescribers : 67

Prescriptions : 115

blank

06

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 119,459,268

Year : 2019

Prescribers : 36038

Prescriptions : 169428

blank

07

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 11,334,892

Year : 2019

Prescribers : 7828

Prescriptions : 18101

blank

08

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 12,485,893

Year : 2018

Prescribers : 8254

Prescriptions : 17481

blank

09

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Amgen

Erenumab-Aooe

Drug Cost (USD) : 6,163,955

Year : 2018

Prescribers : 4790

Prescriptions : 9917

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Regulatory FDF Prices

read-more
read-more

01

Brand Name : Aimovig

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : Aimovig

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Erenumab

Dosage Form : Solution for injection in a pre-...

Dosage Strength : 70 mg/ml

Price Per Pack (Euro) : 217.86

Published in :

Country : Norway

RX/OTC/DISCN :

blank

02

Brand Name : Aimovig

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : Aimovig

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Erenumab

Dosage Form : Solution for injection in a pre-...

Dosage Strength : 140 mg/ml

Price Per Pack (Euro) : 217.86

Published in :

Country : Norway

RX/OTC/DISCN :

blank

03

Brand Name : Aimovig

Denmark
arrow
BIO Partnering at JPM
Not Confirmed

Brand Name : Aimovig

Denmark
arrow
BIO Partnering at JPM
Not Confirmed

Erenumab

Dosage Form : Solution for injection in a pre-...

Dosage Strength : 70 mg/ml

Price Per Pack (Euro) : 217.86

Published in :

Country : Norway

RX/OTC/DISCN :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

U.S.A
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 378

2019 Revenue in Millions : 306

Growth (%) : 24

blank

02

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

U.S.A
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 317

2020 Revenue in Millions : 378

Growth (%) : -16

blank

03

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

Switzerland
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 164

2019 Revenue in Millions : 103

Growth (%) : 59

blank

04

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

Switzerland
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 215

2020 Revenue in Millions : 164

Growth (%) : 31

blank

05

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

U.S.A
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 414

2021 Revenue in Millions : 317

Growth (%) : 31

blank

06

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

Switzerland
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 218

2021 Revenue in Millions : 215

Growth (%) : 1

blank

07

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

Switzerland
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 266

2022 Revenue in Millions : 218

Growth (%) : 22

blank

08

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

Switzerland
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : Neurology

Currency : USD

2024 Revenue in Millions : 312

2023 Revenue in Millions : 266

Growth (%) : 17

blank

09

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

U.S.A
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 119

2017 Revenue in Millions : 0

Growth (%) : New Launch

blank

10

Brand Name : Aimovig

Erenumab

arrow
Biotech Showcase
Not Confirmed

Brand Name : Aimovig

U.S.A
arrow
Biotech Showcase
Not Confirmed

Erenumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 306

2018 Revenue in Millions : 119

Growth (%) : 157

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty